Integrating Immunotherapies in Prostate Cancer.
In recent years, immunotherapy has emerged as a viable and promising treatment for prostate cancer. Beyond sipulecuel-T, phase III trials are evaluating multiple vaccine and immune-based therapies in men with this disease. Evidence suggests that many of these therapies are effective at augmenting immune responses and slowing tumor growth rates. Yet prospective data evaluating these responses as surrogates for survival are still needed. In the absence of validated intermediate markers of response, growing data suggests that patients with more indolent disease are more likely to benefit from immunotherapies. In order to further optimize immunotherapy use, ongoing trials are evaluating its combination with traditional as well as other immune-based treatments. Preliminary data from these trials are promising and are shedding new light on this area.
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bldg 10/ Room 12 N-226, Bethesda, MD, 20892, USA, julius.strauss@nih.gov.
Julius
J
Strauss
Ravi A
RA
Madan
D015703:Antigens, CD / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D017430:Prostate-Specific Antigen / Q000187:drug effects* / Q000276:immunology; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*
D015703:Antigens, CD; D019496:Cancer Vaccines; D017430:Prostate-Specific Antigen